Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/19/15
End: 06/06/18
Due: 06/06/19
Phase: N/A
Priority: Normal
Start: 11/09/20
End: 03/21/22
Due: 03/21/23
Phase: N/A
Priority: Normal
Start: 07/21/20
End: 05/18/23
Due: 05/18/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration | NCT02611778 | Bioeq GmbH | user2@example.com | None | 2015-12-19 | 2018-06-06 | 2019-06-06 | - | - | 2025-07-14 |
| A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis | NCT04595409 | Bioeq GmbH | user2@example.com | None | 2020-11-09 | 2022-03-21 | 2023-03-21 | - | - | 2025-07-14 |
| Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration | NCT04522167 | Bioeq GmbH | user2@example.com | None | 2020-07-21 | 2023-05-18 | 2024-05-18 | - | - | 2025-07-14 |